collection
MENU ▼
Read by QxMD icon Read
search

Essential Readings in Surgical Oncology

shared collection
62 papers 100 to 500 followers University of Toronto General Surgical Oncology Fellowship essential readings
https://www.readbyqxmd.com/read/27664260/gastric-cancer-esmo-clinical-practice-guidelines-for-diagnosis-treatment-and-follow-up
#1
E C Smyth, M Verheij, W Allum, D Cunningham, A Cervantes, D Arnold
No abstract text is available yet for this article.
September 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/20823433/adjuvant-chemotherapy-with-fluorouracil-plus-folinic-acid-vs-gemcitabine-following-pancreatic-cancer-resection-a-randomized-controlled-trial
#2
RANDOMIZED CONTROLLED TRIAL
John P Neoptolemos, Deborah D Stocken, Claudio Bassi, Paula Ghaneh, David Cunningham, David Goldstein, Robert Padbury, Malcolm J Moore, Steven Gallinger, Christophe Mariette, Moritz N Wente, Jakob R Izbicki, Helmut Friess, Markus M Lerch, Christos Dervenis, Attila Oláh, Giovanni Butturini, Ryuichiro Doi, Pehr A Lind, David Smith, Juan W Valle, Daniel H Palmer, John A Buckels, Joyce Thompson, Colin J McKay, Charlotte L Rawcliffe, Markus W Büchler
CONTEXT: Adjuvant fluorouracil has been shown to be of benefit for patients with resected pancreatic cancer. Gemcitabine is known to be the most effective agent in advanced disease as well as an effective agent in patients with resected pancreatic cancer. OBJECTIVE: To determine whether fluorouracil or gemcitabine is superior in terms of overall survival as adjuvant treatment following resection of pancreatic cancer. DESIGN, SETTING, AND PATIENTS: The European Study Group for Pancreatic Cancer (ESPAC)-3 trial, an open-label, phase 3, randomized controlled trial conducted in 159 pancreatic cancer centers in Europe, Australasia, Japan, and Canada...
September 8, 2010: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/26703889/everolimus-for-the-treatment-of-advanced-non-functional-neuroendocrine-tumours-of-the-lung-or-gastrointestinal-tract-radiant-4-a-randomised-placebo-controlled-phase-3-study
#3
RANDOMIZED CONTROLLED TRIAL
James C Yao, Nicola Fazio, Simron Singh, Roberto Buzzoni, Carlo Carnaghi, Edward Wolin, Jiri Tomasek, Markus Raderer, Harald Lahner, Maurizio Voi, Lida Bubuteishvili Pacaud, Nicolas Rouyrre, Carolin Sachs, Juan W Valle, Gianfranco Delle Fave, Eric Van Cutsem, Margot Tesselaar, Yasuhiro Shimada, Do-Youn Oh, Jonathan Strosberg, Matthew H Kulke, Marianne E Pavel
BACKGROUND: Effective systemic therapies for patients with advanced, progressive neuroendocrine tumours of the lung or gastrointestinal tract are scarce. We aimed to assess the efficacy and safety of everolimus compared with placebo in this patient population. METHODS: In the randomised, double-blind, placebo-controlled, phase 3 RADIANT-4 trial, adult patients (aged ≥18 years) with advanced, progressive, well-differentiated, non-functional neuroendocrine tumours of lung or gastrointestinal origin were enrolled from 97 centres in 25 countries worldwide...
March 5, 2016: Lancet
https://www.readbyqxmd.com/read/27554502/results-of-resection-for-recurrent-or-residual-retroperitoneal-sarcoma-after-failed-primary-treatment
#4
Trevor D Hamilton, Amanda J Cannell, Minji Kim, Charles N Catton, Martin E Blackstein, Brendan C Dickson, Rebecca A Gladdy, Carol J Swallow
BACKGROUND: Local recurrence after resection of retroperitoneal sarcoma (RPS) is a common and difficult problem. Gross residual disease after incomplete resection is a particular challenge. The authors reviewed their experience with patients referred for management of recurrent or residual RPS. METHODS: Patients seen at the authors' center from 1996 to 2013 who had undergone resection at an outside institution were identified from a prospective database. Kaplan-Meier survival curves were generated and compared by log-rank analysis...
August 23, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/26363985/locoregional-treatment-versus-no-treatment-of-the-primary-tumour-in-metastatic-breast-cancer-an-open-label-randomised-controlled-trial
#5
RANDOMIZED CONTROLLED TRIAL
Rajendra Badwe, Rohini Hawaldar, Nita Nair, Rucha Kaushik, Vani Parmar, Shabina Siddique, Ashwini Budrukkar, Indraneel Mittra, Sudeep Gupta
BACKGROUND: The role of locoregional treatment in women with metastatic breast cancer at first presentation is unclear. Preclinical evidence suggests that such treatment might help the growth of metastatic disease, whereas many retrospective analyses in clinical cohorts have suggested a favourable effect of locoregional treatment in these patients. We aimed to compare the effect of locoregional treatment with no treatment on outcome in women with metastatic breast cancer at initial presentation...
October 2015: Lancet Oncology
https://www.readbyqxmd.com/read/23491275/axillary-dissection-versus-no-axillary-dissection-in-patients-with-sentinel-node-micrometastases-ibcsg-23-01-a-phase-3-randomised-controlled-trial
#6
RANDOMIZED CONTROLLED TRIAL
Viviana Galimberti, Bernard F Cole, Stefano Zurrida, Giuseppe Viale, Alberto Luini, Paolo Veronesi, Paola Baratella, Camelia Chifu, Manuela Sargenti, Mattia Intra, Oreste Gentilini, Mauro G Mastropasqua, Giovanni Mazzarol, Samuele Massarut, Jean-Rémi Garbay, Janez Zgajnar, Hanne Galatius, Angelo Recalcati, David Littlejohn, Monika Bamert, Marco Colleoni, Karen N Price, Meredith M Regan, Aron Goldhirsch, Alan S Coates, Richard D Gelber, Umberto Veronesi
BACKGROUND: For patients with breast cancer and metastases in the sentinel nodes, axillary dissection has been standard treatment. However, for patients with limited sentinel-node involvement, axillary dissection might be overtreatment. We designed IBCSG trial 23-01 to determine whether no axillary dissection was non-inferior to axillary dissection in patients with one or more micrometastatic (≤2 mm) sentinel nodes and tumour of maximum 5 cm. METHODS: In this multicentre, randomised, non-inferiority, phase 3 trial, patients were eligible if they had clinically non-palpable axillary lymph node(s) and a primary tumour of 5 cm or less and who, after sentinel-node biopsy, had one or more micrometastatic (≤2 mm) sentinel lymph nodes with no extracapsular extension...
April 2013: Lancet Oncology
https://www.readbyqxmd.com/read/27380959/esmo-consensus-guidelines-for-the-management-of-patients-with-metastatic-colorectal-cancer
#7
E Van Cutsem, A Cervantes, R Adam, A Sobrero, J H Van Krieken, D Aderka, E Aranda Aguilar, A Bardelli, A Benson, G Bodoky, F Ciardiello, A D'Hoore, E Diaz-Rubio, J-Y Douillard, M Ducreux, A Falcone, A Grothey, T Gruenberger, K Haustermans, V Heinemann, P Hoff, C-H Köhne, R Labianca, P Laurent-Puig, B Ma, T Maughan, K Muro, N Normanno, P Österlund, W J G Oyen, D Papamichael, G Pentheroudakis, P Pfeiffer, T J Price, C Punt, J Ricke, A Roth, R Salazar, W Scheithauer, H J Schmoll, J Tabernero, J Taïeb, S Tejpar, H Wasan, T Yoshino, A Zaanan, D Arnold
Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC (mCRC) has improved greatly due not only to an increase in the number of patients being referred for and undergoing surgical resection of their localised metastatic disease but also to a more strategic approach to the delivery of systemic therapy and an expansion in the use of ablative techniques. This reflects the increase in the number of patients that are being managed within a multidisciplinary team environment and specialist cancer centres, and the emergence over the same time period not only of improved imaging techniques but also prognostic and predictive molecular markers...
August 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27480354/management-of-recurrent-retroperitoneal-sarcoma-rps-in-the-adult-a-consensus-approach-from-the-trans-atlantic-rps-working-group
#8
(no author information available yet)
INTRODUCTION: Retroperitoneal soft tissue sarcomas (RPS) are rare tumors. Surgery is the mainstay of curative therapy, but local recurrence is common. No recommendations concerning the best management of recurring disease have been developed so far. Although every effort should be made to optimize the initial approach, recommendations to treat recurring RPS will be helpful to maximize disease control at recurrence. METHODS: An RPS transatlantic working group was established in 2013...
October 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27513155/locoregional-recurrence-after-sentinel-lymph-node-dissection-with-or-without-axillary-dissection-in-patients-with-sentinel-lymph-node-metastases-long-term-follow-up-from-the-american-college-of-surgeons-oncology-group-alliance-acosog-z0011-randomized-trial
#9
Armando E Giuliano, Karla Ballman, Linda McCall, Peter Beitsch, Pat W Whitworth, Peter Blumencranz, A Marilyn Leitch, Sukamal Saha, Monica Morrow, Kelly K Hunt
BACKGROUND AND OBJECTIVE: The early results of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial demonstrated no difference in locoregional recurrence for patients with positive sentinel lymph nodes (SLNs) randomized either to axillary lymph node dissection (ALND) or sentinel lymph node dissection (SLND) alone. We now report long-term locoregional recurrence results. METHODS: ACOSOG Z0011 prospectively examined overall survival of patients with SLN metastases undergoing breast-conserving therapy randomized to undergo ALND after SLND or no further axillary specific treatment...
September 2016: Annals of Surgery
https://www.readbyqxmd.com/read/26556476/use-of-preoperative-magnetic-resonance-imaging-to-select-patients-with-rectal-cancer-for-neoadjuvant-chemoradiation-interim-analysis-of-the-german-ocum-trial-nct01325649
#10
MULTICENTER STUDY
Martin E Kreis, R Ruppert, H Ptok, J Strassburg, P Brosi, A Lewin, M R Schön, J Sauer, T Junginger, S Merkel, P Hermanek
INTRODUCTION: Introduction of total mesorectal excision (TME) surgery for rectal cancer decreased local recurrence dramatically. Additional neoadjuvant chemoradiation (nCR) is frequently given in UICC II and III tumors based on TNM staging which is of limited accuracy. We aimed to evaluate determination of circumferential margin by magnetic resonance imaging (mrCRM) as an alternative criterium for nCR. METHODS: Multicenter prospective cohort study which enrolled 642 patients in 13 centers with non-metastasized rectal adenocarcinoma...
January 2016: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/27247216/locally-advanced-unresectable-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline
#11
Edward P Balaban, Pamela B Mangu, Alok A Khorana, Manish A Shah, Somnath Mukherjee, Christopher H Crane, Milind M Javle, Jennifer R Eads, Peter Allen, Andrew H Ko, Anitra Engebretson, Joseph M Herman, John H Strickler, Al B Benson, Susan Urba, Nelson S Yee
PURPOSE: To provide evidence-based recommendations to oncologists and others for treatment of patients with locally advanced, unresectable pancreatic cancer. METHODS: American Society of Clinical Oncology convened an Expert Panel of medical oncology, radiation oncology, surgical oncology, gastroenterology, palliative care, and advocacy experts and conducted a systematic review of the literature from January 2002 to June 2015. Outcomes included overall survival, disease-free survival, progression-free survival, and adverse events...
August 1, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27236421/diagnosis-and-management-of-gastrointestinal-neuroendocrine-tumors-an-evidence-based-canadian-consensus
#12
REVIEW
Simron Singh, Sylvia L Asa, Chris Dey, Hagen Kennecke, David Laidley, Calvin Law, Timothy Asmis, David Chan, Shereen Ezzat, Rachel Goodwin, Ozgur Mete, Janice Pasieka, Juan Rivera, Ralph Wong, Eva Segelov, Daniel Rayson
The majority of neuroendocrine tumors originate in the digestive system and incidence is increasing within Canada and globally. Due to rapidly evolving evidence related to diagnosis and clinical management, updated guidance on the diagnosis and treatment of gastrointestinal neuroendocrine tumors (GI-NETs) are of clinical importance. Well-differentiated GI-NETs may exhibit indolent clinical behavior and are often metastatic at diagnosis. Some NET patients will develop secretory disease requiring symptom control to optimize quality of life and clinical outcomes...
June 2016: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/18650514/sorafenib-in-advanced-hepatocellular-carcinoma
#13
RANDOMIZED CONTROLLED TRIAL
Josep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Jean-Frédéric Blanc, Andre Cosme de Oliveira, Armando Santoro, Jean-Luc Raoul, Alejandro Forner, Myron Schwartz, Camillo Porta, Stefan Zeuzem, Luigi Bolondi, Tim F Greten, Peter R Galle, Jean-François Seitz, Ivan Borbath, Dieter Häussinger, Tom Giannaris, Minghua Shan, Marius Moscovici, Dimitris Voliotis, Jordi Bruix
BACKGROUND: No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma. METHODS: In this multicenter, phase 3, double-blind, placebo-controlled trial, we randomly assigned 602 patients with advanced hepatocellular carcinoma who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or placebo...
July 24, 2008: New England Journal of Medicine
https://www.readbyqxmd.com/read/26361969/adjuvant-sorafenib-for-hepatocellular-carcinoma-after-resection-or-ablation-storm-a-phase-3-randomised-double-blind-placebo-controlled-trial
#14
RANDOMIZED CONTROLLED TRIAL
Jordi Bruix, Tadatoshi Takayama, Vincenzo Mazzaferro, Gar-Yang Chau, Jiamei Yang, Masatoshi Kudo, Jianqiang Cai, Ronnie T Poon, Kwang-Hyub Han, Won Young Tak, Han Chu Lee, Tianqiang Song, Sasan Roayaie, Luigi Bolondi, Kwan Sik Lee, Masatoshi Makuuchi, Fabricio Souza, Marie-Aude Le Berre, Gerold Meinhardt, Josep M Llovet
BACKGROUND: There is no standard of care for adjuvant therapy for patients with hepatocellular carcinoma. This trial was designed to assess the efficacy and safety of sorafenib versus placebo as adjuvant therapy in patients with hepatocellular carcinoma after surgical resection or local ablation. METHODS: We undertook this phase 3, double-blind, placebo-controlled study of patients with hepatocellular carcinoma with a complete radiological response after surgical resection (n=900) or local ablation (n=214) in 202 sites (hospitals and research centres) in 28 countries...
October 2015: Lancet Oncology
https://www.readbyqxmd.com/read/26822397/gastrectomy-plus-chemotherapy-versus-chemotherapy-alone-for-advanced-gastric-cancer-with-a-single-non-curable-factor-regatta-a-phase-3-randomised-controlled-trial
#15
RANDOMIZED CONTROLLED TRIAL
Kazumasa Fujitani, Han-Kwang Yang, Junki Mizusawa, Young-Woo Kim, Masanori Terashima, Sang-Uk Han, Yoshiaki Iwasaki, Woo Jin Hyung, Akinori Takagane, Do Joong Park, Takaki Yoshikawa, Seokyung Hahn, Kenichi Nakamura, Cho Hyun Park, Yukinori Kurokawa, Yung-Jue Bang, Byung Joo Park, Mitsuru Sasako, Toshimasa Tsujinaka
BACKGROUND: Chemotherapy is the standard of care for incurable advanced gastric cancer. Whether the addition of gastrectomy to chemotherapy improves survival for patients with advanced gastric cancer with a single non-curable factor remains controversial. We aimed to investigate the superiority of gastrectomy followed by chemotherapy versus chemotherapy alone with respect to overall survival in these patients. METHODS: We did an open-label, randomised, phase 3 trial at 44 centres or hospitals in Japan, South Korea, and Singapore...
March 2016: Lancet Oncology
https://www.readbyqxmd.com/read/26338525/folfoxiri-plus-bevacizumab-versus-folfiri-plus-bevacizumab-as-first-line-treatment-of-patients-with-metastatic-colorectal-cancer-updated-overall-survival-and-molecular-subgroup-analyses-of-the-open-label-phase-3-tribe-study
#16
RANDOMIZED CONTROLLED TRIAL
Chiara Cremolini, Fotios Loupakis, Carlotta Antoniotti, Cristiana Lupi, Elisa Sensi, Sara Lonardi, Silvia Mezi, Gianluca Tomasello, Monica Ronzoni, Alberto Zaniboni, Giuseppe Tonini, Chiara Carlomagno, Giacomo Allegrini, Silvana Chiara, Mauro D'Amico, Cristina Granetto, Marina Cazzaniga, Luca Boni, Gabriella Fontanini, Alfredo Falcone
BACKGROUND: In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab significantly improved progression-free survival of patients with metastatic colorectal cancer compared with FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus bevacizumab. In this updated analysis, we aimed to provide mature results for overall survival-a secondary endpoint-and report treatment efficacy in RAS and BRAF molecular subgroups. METHODS: TRIBE was an open-label, multicentre, phase 3 randomised study of patients (aged 18-70 years with Eastern Cooperative Oncology Group [ECOG] performance status of 2 or less and aged 71-75 years with an ECOG performance status of 0) with unresectable metastatic colorectal cancer who were recruited from 34 Italian oncology units...
October 2015: Lancet Oncology
https://www.readbyqxmd.com/read/26200977/regional-nodal-irradiation-in-early-stage-breast-cancer
#17
RANDOMIZED CONTROLLED TRIAL
Timothy J Whelan, Ivo A Olivotto, Wendy R Parulekar, Ida Ackerman, Boon H Chua, Abdenour Nabid, Katherine A Vallis, Julia R White, Pierre Rousseau, Andre Fortin, Lori J Pierce, Lee Manchul, Susan Chafe, Maureen C Nolan, Peter Craighead, Julie Bowen, David R McCready, Kathleen I Pritchard, Karen Gelmon, Yvonne Murray, Judy-Anne W Chapman, Bingshu E Chen, Mark N Levine
BACKGROUND: Most women with breast cancer who undergo breast-conserving surgery receive whole-breast irradiation. We examined whether the addition of regional nodal irradiation to whole-breast irradiation improved outcomes. METHODS: We randomly assigned women with node-positive or high-risk node-negative breast cancer who were treated with breast-conserving surgery and adjuvant systemic therapy to undergo either whole-breast irradiation plus regional nodal irradiation (including internal mammary, supraclavicular, and axillary lymph nodes) (nodal-irradiation group) or whole-breast irradiation alone (control group)...
July 23, 2015: New England Journal of Medicine
https://www.readbyqxmd.com/read/24825641/effect-of-pet-before-liver-resection-on-surgical-management-for-colorectal-adenocarcinoma-metastases-a-randomized-clinical-trial
#18
RANDOMIZED CONTROLLED TRIAL
Carol-Anne Moulton, Chu-Shu Gu, Calvin H Law, Ved R Tandan, Richard Hart, Douglas Quan, Robert J Fairfull Smith, Diederick W Jalink, Mohamed Husien, Pablo E Serrano, Aaron L Hendler, Masoom A Haider, Leyo Ruo, Karen Y Gulenchyn, Terri Finch, Jim A Julian, Mark N Levine, Steven Gallinger
IMPORTANCE: Patients with colorectal cancer with liver metastases undergo hepatic resection with curative intent. Positron emission tomography combined with computed tomography (PET-CT) could help avoid noncurative surgery by identifying patients with occult metastases. OBJECTIVES: To determine the effect of preoperative PET-CT vs no PET-CT (control) on the surgical management of patients with resectable metastases and to investigate the effect of PET-CT on survival and the association between the standardized uptake value (ratio of tissue radioactivity to injected radioactivity adjusted by weight) and survival...
May 14, 2014: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/25559811/phase-iii-trial-to-compare-adjuvant-chemotherapy-with-capecitabine-and-cisplatin-versus-concurrent-chemoradiotherapy-in-gastric-cancer-final-report-of-the-adjuvant-chemoradiotherapy-in-stomach-tumors-trial-including-survival-and-subset-analyses
#19
RANDOMIZED CONTROLLED TRIAL
Se Hoon Park, Tae Sung Sohn, Jeeyun Lee, Do Hoon Lim, Min Eui Hong, Kyoung-Mee Kim, Insuk Sohn, Sin Ho Jung, Min Gew Choi, Jun Ho Lee, Jae Moon Bae, Sung Kim, Seung Tae Kim, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang
PURPOSE: The Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) trial tested whether the addition of radiotherapy to adjuvant chemotherapy improved disease-free survival (DFS) in patients with D2-resected gastric cancer (GC). PATIENTS AND METHODS: Between November 2004 and April 2008, 458 patients with GC who received gastrectomy with D2 lymph node dissection were randomly assigned to either six cycles of adjuvant chemotherapy with capecitabine and cisplatin (XP) or to two cycles of XP followed by chemoradiotherapy and then two additional cycles of XP (XPRT)...
October 1, 2015: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/26462967/2015-american-thyroid-association-management-guidelines-for-adult-patients-with-thyroid-nodules-and-differentiated-thyroid-cancer-the-american-thyroid-association-guidelines-task-force-on-thyroid-nodules-and-differentiated-thyroid-cancer
#20
REVIEW
Bryan R Haugen, Erik K Alexander, Keith C Bible, Gerard M Doherty, Susan J Mandel, Yuri E Nikiforov, Furio Pacini, Gregory W Randolph, Anna M Sawka, Martin Schlumberger, Kathryn G Schuff, Steven I Sherman, Julie Ann Sosa, David L Steward, R Michael Tuttle, Leonard Wartofsky
BACKGROUND: Thyroid nodules are a common clinical problem, and differentiated thyroid cancer is becoming increasingly prevalent. Since the American Thyroid Association's (ATA's) guidelines for the management of these disorders were revised in 2009, significant scientific advances have occurred in the field. The aim of these guidelines is to inform clinicians, patients, researchers, and health policy makers on published evidence relating to the diagnosis and management of thyroid nodules and differentiated thyroid cancer...
January 2016: Thyroid: Official Journal of the American Thyroid Association
label_collection
label_collection
3553
1
2
2015-10-31 04:08:20
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"